The French Data Protection Agency (CNIL) has been actively supporting digital health technology innovators through its regulatory “sandbox.” These projects range from federated learning across health data warehouses to building diagnostic tools in oncology, statistical indicators for medical research, and a therapeutic game for minors with eating disorders. The CNIL provides crucial guidance on overcoming regulatory challenges, including the nature of data, legal frameworks, and data security measures.
Benefits for RWD, RWE, and Digital Health Innovators:
- Navigating Regulatory Challenges: The CNIL’s sandbox provides a safe environment to test solutions and understand regulations. For RWD and RWE developers, this means an easier path to compliance with GDPR and other privacy laws.
- Interconnected Data Sources: For projects like Resilience in oncology, CNIL’s guidance enabled the interconnection of various data sources. This has implications for RWD, as it becomes easier to integrate data from disparate sources for more comprehensive Real-World Evidence.
- Data Security: With its focus on secure data processing, the sandbox offers a blueprint for ensuring the safety of health data, which is invaluable for digital health innovators dealing with sensitive patient information.
- AI and Machine Learning: Projects like the one carried out at Lille University Hospital utilized federated learning protocols, offering a roadmap for implementing machine learning algorithms in healthcare. This aids RWD and RWE applications where machine learning could provide new insights.
- Specialized Use-Cases: The Vertexica project focusing on minors with eating disorders shows how data protection can be maintained even in specialized healthcare solutions, thereby ensuring the ethical use of Real-World Data.
- Knowledge Sharing: The joint work and multiple exchanges with CNIL have generated lessons that could be useful for the broader health sector, facilitating faster and more secure innovation.
- ‘Privacy by Design’: The emphasis on integrating GDPR compliance from the design phase benefits all stakeholders by baking in data protection from the outset, which is a fundamental need in RWD and RWE applications.
- Stakeholder Collaboration: The sandbox projects involve multi-disciplinary teams, demonstrating a collaborative approach that could benefit digital health innovators, RWD and RWE developers in addressing complex regulatory and ethical issues.
In essence, the CNIL’s regulatory sandbox serves as an invaluable resource, not just as a testing ground but as a knowledge base for RWD, RWE, and digital health innovators. It provides practical insights into overcoming regulatory challenges and implementing secure, effective healthcare solutions.
Share this story...
Germany – AKEK – Secondary Use of Patient Data for Research Purposes
RWE 201 - Germany – AKEK – Secondary Use of Patient Data for Research Purposes AKEK Statement (Aug 2023): https://www.akek.de/wp-content/uploads/Stellungnahme-EHDS_V7.1.pdfThe Working Group of Medical Ethics Commissions in Germany (AKEK) [...]
UK – NHS England – Federated Data Platform – Lessons Learned from the General Practice Data for Planning and Research Initiative
RWE 201 - UK – NHS England – Federated Data Platform – Lessons Learned from the General Practice Data for Planning and Research Initiative NHS England – Federated Data [...]
UK – NICE – RWE Framework
RWE 201 - UK – NICE – RWE Framework NICE RWE Framework: https://www.nice.org.uk/corporate/ecd9/chapter/overviewReal-world data (RWD) encompasses various types of information on patient health, care delivery, and experiences collected outside [...]
UK – MHRA – Randomised Controlled Trials Using Real World Data
RWE 201 - UK – MHRA – Randomised Controlled Trials Using Real World Data MHRA RWD Guidance: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guideline-on-randomised-controlled-trials-using-real-world-data-to-support-regulatory-decisions The MHRA guideline focuses on sponsors planning to [...]
UK – MHRA – Use of RWD to Support Regulatory Decisions
RWE 201 - UK – MHRA – Use of RWD to Support Regulatory Decisions MHRA RWD Guidance: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions The MHRA (Medicines and Healthcare products Regulatory Agency) [...]
Real World Evidence (RWE) 201 – France – Haute Autorité de Santé (HAS) – Real World Study Guide
RWE 201 - France – Haute Autorité de Santé (HAS) – Real World Study Guide HAS Real World Stidy Guide: https://www.has-sante.fr/upload/docs/application/pdf/2021-06/real-world_studies_for_the_assessment_of_medicinal_products_and_medical_devices.pdfThe Haute Autorité de Santé (HAS), France's National Authority [...]







